FDA OKs telmisartan for hypertension
FDA OKs telmisartan for hypertension
The Food and Drug Administration (FDA)approved the angiotensin II receptor blocker, telmisartan (Boehringer Ingelheim’s Micardis), for the management of hypertensive patients. In clinical trials, a once-daily dose of telmisartan effectively controlled hypertension in up to 65% of patients and has been shown to be effective when compared to treatment with amlodipine, enalapril, and losartan. The drug was well toler-ated, with the incidence of adverse effects similar to that seen in patients receiving placebos.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.